Document is current
Any future updates will be listed below
-
Authors
Chen, Athena
Kammers, Kai
Larman, H Benjamin
Scharpf, Robert B.
Ruczinski, Ingo
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (GM136724, GM136724, GM136724, GM136724)
National Institute of Allergy and Infectious Diseases (AI095068)
National Cancer Institute (CA062924)
- License Information
-
More Information
Article History
Received: 2 February 2022
Accepted: 31 August 2022
First Online: 15 September 2022
Declarations
:
: The HIV elite controller data [] and the CoronaScan data [] were generated in previous studies from individuals who provided their written informed consent to participate in this study. The parent studies from which the samples had originated were approved by the Johns Hopkins School of Medicine Institutional Review Board (IRB #s NA_00051773, NA_00093758 and NA_00028825) and by the Walter Reed Army Institute of Research (IRB00000794). The research had been conducted in accordance with the principles expressed by the Declaration of Helsinki.
: Not applicable.
: H.B.L. is an inventor on a patent describing the VirScan technology (US patent no. 15/105,722). H.B.L. is a founder of Portal Bioscience, Alchemab and ImmuneID, and is an advisor to TScan Therapeutics. R.B.S. is a founder and consultant of Delfi Diagnostics, and owns Delfi Diagnostics stock subject to certain restrictions under university policy. Johns Hopkins University owns equity in Delfi Diagnostics and Portal Bioscience.
